Boggs, Vice President of R&D at SPR Therapeutics, to Serve Second Term on the Secretary of Veterans Affairs' Advisory Committee on Prosthetics and Special Disabilities Programs. Read the full article (PDF)
More Physicians Seek Interventional Therapies for Acute and Chronic Pain; Top Pain Doctors Praise New Peripheral Nerve Stimulation System from SPR Therapeutics Read the full article (PDF)
The moderate-to-severe pain many patients experience after orthopedic surgery is often treated with opioids, which are associated with undesirable adverse effects such as nausea, vomiting, sedation, and respiratory depression. Read the full article (PDF)
© 2021 SPR Therapeutics
The SPRINT PNS System is indicated for up to 60 days in the back and/or extremities for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the craniofacial region. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.
View References for support of all claims.
The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.